DEFUZIN-BETAV CREAM [SIN17417P]
Active ingredients: BETAMETHASONE VALERATE EQV BETAMETHASONE | FUSIDIC ACID
Last updated on 9 October 2026
Product Info
DEFUZIN-BETAV CREAM
[SIN17417P]
Product information
Active Ingredient and Strength | BETAMETHASONE VALERATE EQV BETAMETHASONE - 0.1 G/100 G |
Dosage Form | CREAM |
Manufacturer and Country | ENCUBE ETHICALS PVT. LTD. - INDIA |
Registration Number | SIN17417P |
Licence Holder | APEX PHARMA MARKETING PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | D07CC01 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
INDICATIONS
Defuzin-BetaV is indicated for inflammatory dermatoses where bacterial infection is present or likely to occur. Inflammatory dermatoses include atopic eczema, discoid eczema, stasis eczema, seborrhoeic dermatitis, contact dermatitis, lichen simplex chronicus, psoriasis, discoid lupus erythematosus.
Dosing
DOSAGE AND ADMINISTRATION
Uncovered lesions: 2–3 daily applications.
Covered lesions: Less frequent application may be adequate
Method of Administration
For external use only.
Contraindications
CONTRAINDICATIONS
Hypersensitivity to fusidic acid/ sodium fusidate, betamethasone valerate or to any of the excipients.
Due to the content of corticosteroid, it is contraindicated in the following conditions: Systemic fungal infections.
Primary skin infections caused by fungi, virus or bacteria, either untreated or uncontrolled by appropriate treatment (see WARNINGS AND PRECAUTIONS – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Skin manifestations in relation to tuberculosis, either untreated or uncontrolled by appropriate therapy.
Perioral dermatitis and rosacea.